Motor segmentation: a key neuromuscular impairment in people with Parkinson’s disease.
This note indexes a cited or audit-added source. It may be an original study, review, guideline, form or methods reference. Treat the specific design and the evidence below as authoritative; a source note is not automatically a primary study.
DOI: 10.1007/s00221-025-07189-3
Bibliographic record from the original reports
Access labels embedded in these original reference strings are historical. Current access and exact checked components are stated separately below.
Daniels RJ, Knight CA. Motor segmentation: a key neuromuscular impairment in people with parkinson’s disease. Experimental Brain Research. 2025;243(12):241. DOI 10.1007/s00221-025-07189-3
Conditions: COND-PD Parkinson’s disease
Scoped audit evidence
These are source- and component-level audit summaries as of 3 October 2026. Access and comparison scope can differ by report; none certifies every result or the underlying raw data.
Parkinson’s disease — strength
- access status: full_main_text_available
STR-14-02
STR-14-01
Limitations: Only current scoped checks; archived captures not authenticated against live originals.
Parkinson’s disease strength
- current access: full_main_text_available
- primary version: PMC full article; version not independently compared to publisher PDF
Parkinson’s disease strength component — Segmentation cohort, prevalence and complete reported assay bundle
Methods and Results match 57 PD/22 controls, 39/57 segmented (68%, CI 55–80%), index-finger apparatus and angles, 200/50-Hz sampling/filter, five 60-second trials, 41 selected pulses, 50-ms derivatives and 20% MVC/s onset criterion.
Source locator: Methods and Results; Tables 1–2
Limitations: AI-assisted source comparison; no raw-data verification.
Parkinson’s disease strength component — Residual segmentation classification and population limits
Methods defines segmentation from the same randomly selected 41 force pulses used for timing comparisons, with median segments to 90%peak≥2. Results and limitations identify an ON-medication, HY 1–3, predominantly male cohort; timing/dose varied and cognition was incompletely measured. This supports the report’s phenotype and generalizability cautions; no prospective prognostic validation was performed.
Source locator: https://doi.org/10.1007/s00221-025-07189-3; audit evidence record, Methods/Results/Limitations
Limitations: AI-assisted source comparison; no raw-data verification.
Reports citing this source
- Strength muscle power and rapid force production assessment in Parkinson’s disease · reference 14 · original reference
Update record
- 2026-10-03: Created from the supplied reports and final scoped audit. New evidence should be appended with source version, access date, exact locator and affected report links.
Updating the wiki · Evidence and status guide